| Subscribe To Our Free Newsletter |
Marksans Pharma stock zooms 16% to hit record high on strong Q1 results
The US & North America Formulation biz reported growth of 29.8% YoY in Q1FY25, on account of incremental revenue from new product launches, and increase in the share of existing customers.
